公司2024 年收入155.7 百万元,去年同期63.5 百万元,2024 年收入均来自艾力斯合作收入。2024 年研发费用330.2 百万元,去年同期372.3 百万元,2024 年行政开支43.1 百万元,去年同期46.6 百万元。归母净利润-155.7百万元,去年同期-359.1 百万元。Glecirasib 多适应症同步推进,预计2025H1 获批治疗2 线非小细胞肺癌适应症。1)单药治疗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.